Quick links: Bone • Fatigue • Involuntary Weight Loss • Nausea/Vomiting • Oral Care • Pain • Quality of Care

Bone

PA-1

Nontraumatic Vertebral Fractures in Patients With Locally Advanced Esophageal Cancer: A Previously Unreported, Unrecognized Problem
Heidi A. McKean, Robert C. Miller, and Aminah Jatoi

Mayo Clinic College of Medicine, Rochester, Minnesota

Fatigue

PA-2

Fatigue and Associated Changes in Activity and Fitness During Adjuvant Breast Radiotherapy
Peter A. J. Hope,¹ Robert U. Newton,¹ Paul Sacco,^1,2 Linda Kristjanson,^1,3 and Nigel Spry⁴

¹Edith Cowan University, Perth, Australia; ²East London University, Stratford, London, United Kingdom; ³Curtin University, Perth, Australia; and ⁴Sir Charles Gairdner Hospital, Perth, Australia

poster

152 kb

PA-3

Reducing the Stress of Repeated Assessments: a Comparison of Multidimensional Fatigue Inventory and Visual Analogue Scale in Adjuvant Breast Radiotherapy
Peter A. J. Hope,¹ Robert U. Newton,¹ Paul Sacco,^1,2 Linda Kristjanson,^1,3 and Nigel Spry⁴

¹Edith Cowan University, Perth, Australia; ²East London University, Stratford, London, United Kingdom; ³Curtin University, Perth, Australia; and ⁴Sir Charles Gairdner Hospital, Perth, Australia

poster

102 kb

Involuntary Weight Loss

PA-4

The Impact of Automatic Nutritional Referral Based on a Patient-Generated Standardized Assessment Tool
Debra DeMille and Cathy Fortenbaugh

Pennsylvania Oncology Hematology Associates, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, Pennsylvania

PA-5

Oral Zinc for Chemotherapy-Related Taste and Smell Disorders: A Pilot Study
Laurel J. Lyckholm,¹ Steven P. Heddinger,² Gwendolyn G. Parker,¹ Robert I. Henkin,³ Viswanathan Ramakrishnan,¹ and Thomas J. Smith¹

¹Massey Cancer Center and Virginia Commonwealth University, Richmond, and ²Des Moines Hematology/Oncology, Des Moines, Iowa; and ³The Center for Molecular Nutrition and Sensory Disorders, Washington, DC

PA-6

Safety and Efficacy of Anti-TNF-a Antibody Infliximab Plus Gemcitabine in Pancreatic Cancer Cachexia: Results of a Multicenter, Phase II Study
Bertram Wiedenmann,¹ Peter Malfertheiner,² Paul Ritch,³ Dan Von Hoff,⁴ Ming Qi,⁵ Don Robinson, Jr.,⁵ Bob Zhong,⁵ and Mark DeWitte⁵

¹Universitätsklinikum Charite, Berlin, Germany; ²Universitätsklinikum Otto-von-Guericke Universität, Magdeburg, Germany; ³Medical College of Wisconsin, Madison; ⁴Translational Genetic Research Institute and Arizona Cancer Center, Phoenix; and ⁵Centocor Research & Development, Inc., Horsham, Pennsylvania

Nausea/Vomiting

PA-7

Multiple-Day Palonosetron Antiemetic Regimen Is Safe and Effective for Preventing Chemotherapy-Induced Nausea and Vomiting in Patients Receiving 5-Day Cisplatin for Testicular Cancer
Tim DeGroot,¹ Lawrence Einhorn,² Jackie Brames,² Bruce J. Roth,³ Robert Dreicer,⁴ Craig Nichols,⁵ and Joseph Bubalo⁵

¹MGI PHARMA, Inc., Bloomington, Minnesota; ²Indiana University Medical Center, Indianapolis; ³Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee; ⁴The Cleveland Clinic, Cleveland, Ohio; and ⁵Oregon Health & Science University, Portland

poster

261 kb

PA-8

Chemotherapy-Induced Nausea and Vomiting: Healthcare Provider Perceptions and Outcomes in Participants Treated With Moderately Emetogenic Chemotherapy
Susan Weidner

¹MGI PHARMA, Inc., Bloomington, Minnesota

poster

327 kb

PA-9

Ondansetron HCl Oral Spray Versus Ondansetron Oral Tablet—Bioavailability and Safety by Gender
Wayne Yates, Biao Lu, Marek Wolter, Sandra Nino, and Gregory I. Berk

Hana Biosciences, Inc., South San Francisco, California

Oral Care

PA-10

Patient-Reported Outcomes of Severe Mouth Sore Scores in the Community Oncology Setting
Carl de Moor,^1,2 Barry V. Fortner,¹ Arthur C. Houts,¹ and Susan Weidner³

¹Supportive Oncology Services, Inc., Memphis, Tennessee; ²Harvard Medical School, Boston, Massachusetts; and ³MGI PHARMA, Inc., Bloomington, Minnesota

PA-11

Gingival and Periodontal Disorders in Children and Adolescents With Special Reference in Oral Health, Suffering From Malignancy
Jalaleddin Hamissi

Qazvin Dental College, Qazvin, Iran

Pain

PA-12

The Most Frequently Used Oral Breakthrough Pain Medications in Oncology Inpatients
Jane Rosati, Carolyn R. Thomas, Ned Buffington, and Sharon Conley

AVANCEN LLC, Ormond Beach, Florida

poster

163 kb

PA-13

Pain Alleviation After Percutaneous Bone Augmentation With Plasma-Mediated Radiofrequency Ablation for Vertebral Compression Fractures Due to Malignancy
Bassem A. Georgy and Wade Wong

University of California at San Diego, La Jolla

PA-14

The Role of Controlled-Release Dihydrocodeine and Tramadol in Cancer Pain Treatment—A Polish Experience
Wojciech Leppert

Pozna´n University of Medical Sciences, Poznán, Poland

Quality of Care

PA-15

Human Resource Costs Associated With Management of Adverse Events in Community Oncology: A Multisite Survey of Administrators and Healthcare Professionals
Barry V. Fortner, Arthur C. Houts, and Ling Zhu

Supportive Oncology Services, Inc., Memphis, Tennessee

PA-16

A Comparison of Hematology/Oncology Clinic Attendance Between Insured and Underinsured Patients at an Urban Academic Hospital: Identifying Barriers and Ways to Overcome Them
John A. Youssef, Laurel J. Lyckholm, Thomas J. Smith, Lisa Shickle, Gwendolyn G. Parker, and Robin Matsuyama

Virginia Commonwealth University and Massey Cancer Center, Richmond, Virginia

PA-17

Human Resource Implications of Intravenous Monoclonal Antibody Infusion Reactions: Time and Motion Pilot Study
Barry V. Fortner, Lee S. Schwartzberg, Edward J. Stepanski, Dongyue Fu, and Tai Bibbs

Accelerated Community Oncology Research Network, Memphis, Tennessee

PA-18

Changes in Concentration and Memory: Life After Cancer Program
Cindy Waddington, Jeff Kendall, and Sue Brebner

Helen F. Graham Cancer Center, Christiana Care Health System, Newark, Delaware

poster

243 kb

© 2007 by Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.